Abbosh, Christopher
Birkbak, Nicolai J.
Swanton, Charles
Article History
First Online: 3 July 2018
Competing interests
: C.A. and C.S. submitted a patent with University College London (UCL) business PLC (provisional patent number 1618485.5) based on a phylogenetic approach to analysis of circulating tumour DNA. C.S. has received grant support from AstraZeneca; personal fees from Boehringer Ingelheim, Celgene, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and Roche; has stock options in Achilles Therapeutics, ApoGen Biotechnologies, EPIC Bioscience, and GRAIL; and is a co-founder of Achilles Therapeutics. N.J.B. declares no competing interests.